TScan Therapeutics宣布:关键性III期试验Alloha-2™完成首例患者给药,评估Tsc-101治疗血液恶性肿瘤效果

美股速递
Jul 29

TScan Therapeutics公司正式宣告,其针对血液恶性肿瘤的III期关键性试验Alloha-2™已完成首例患者给药。该试验旨在评估核心候选药物Tsc-101的疗效与安全性,这标志着公司在血液肿瘤治疗领域迈出了重要一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10